Abstract 617P
Background
Ewing sarcoma is a neoplasm of neuroectodermal origin arising from bone or soft tissue. The annual incidence of Ewing sarcoma in children is 2.93 per 1,000,000. Acute myeloid leukaemia (AML) is one of the most common malignancies as a complication of primary cancer therapy. There are very few studies reported the association of Ewing sarcoma with AML. So, our aim is to quantify the risk of developing AML in Ewing sarcoma patients and provide updated evidence to the literature.
Methods
We extracted the data from the surveillance, Epidemiology and End Results (SEER) statistical analysis software package (SEER*Stat, version 8.4.1.2). We used the MP-SIR session to identify patients who had ewing sarcoma as a first primary tumor, then diagnosed with acute myeloid leukaemia as a second primary malignancy between 2000 and 2020. We assessed the SIR as Observed/Expected(O/E) and Excess Absolute Risk (EAR) per 10,000 with a 95% Confidence Interval (CI) and statistical significance at P<0.05.
Results
A total of 2631 patients had a median follow-up of 120+ months. Patient with Ewing sarcoma had an increased risk to develop AML with O/E of 145.98 (95% CI:101.68 -203.03, P<0.05, EAR= 21.79). The total cohort of patients had a PC of 32.7, APC of 1.3 (95% CI: 0.6 -2.0; P<0.05. Female patients had a PC of 46.5, APC of 1.7 (95% CI: 0.5 -2.9; P<0.05). about 35 patients developed acute non lymphocytic leukaemia (ANLL) with O/E 130.92 (95% [CI] 91.19 -182.08; P<0.05, EAR 21.77).
Conclusions
Ewing sarcoma is a very rare tumor that it is hard to assess the risk of multiple primary malignancies associated with it. In this study we found patients who developed a primary Ewing sarcoma had significantly high risk of developing Acute myeloid leukemia especially in the first year after diagnosis, so we recommend to start screening for AML once Ewing sarcoma is diagnosed for early detection and better management plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract